Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Regulatory Routine +

Apotex Health Corp. (APTX) Opens the Market

Canadian pharma giant completes $1.3B IPO, debuts on TSX with a 12.5% pop.

Executive Summary
  • The most recent release (June 11, 2026) details the official market opening and bell-ringing ceremony for Apotex Health Corp. (APTX) on the Toronto Stock Exchange.
  • This ceremonial event follows the successful pricing of its upsized IPO on June 9 at $24.00 per share, which raised $1.3 billion in gross proceeds.
  • The capital raise is structured as a primary treasury offering (~$850M to Apotex) and a secondary offering by existing shareholders (~$450M), with an over-allotment option for up to 8.125M additional shares.
  • The announcement highlights the company's position as the largest Canadian-based pharmaceutical firm and its global operational footprint across the Americas.
Material Impact
  • The bell-ringing ceremony is a procedural milestone that confirms the completion of the listing process initiated on June 10. It carries no new financial, operational, or strategic data.
  • The material pricing event occurred on June 9-10. The stock opened at $27.00 on June 10, reflecting a 12.5% premium over the $24.00 IPO price. This pop indicates strong initial demand and successful execution.
  • The $1.3B gross raise significantly strengthens the balance sheet, providing substantial liquidity for future acquisitions, R&D, and debt reduction. However, the June 11 news itself does not alter the capital structure or valuation.
APTX · Price
Company Overview
  • Apotex Health Corp. is the largest Canadian-based pharmaceutical company, headquartered in Toronto with regional offices in the US, Mexico, and India.
  • The company operates across generic, biosimilar, and innovative branded pharmaceuticals, alongside consumer health products.
  • It holds a strategic position as a preferred health partner in the Americas for pharmaceutical licensing and product acquisitions.
  • The company is backed by major private equity owners, including SK Artemis Holdings, II, LLC (~54.3% post-IPO) and API Investment LP (~14.0%).
Read the original news release →

More from APOTEX HEALTH CORP